![]() |
|
|
Vol. 59, Issue 3, 462-469, March 2001
Screening Technologies Branch, Developmental Therapeutics Program,
Division of Cancer Treatment and Diagnosis, National Cancer Institute
at Frederick, National Institutes of Health, Frederick, Maryland (R.B.,
P.V.-P., E.H.); Department of Chemistry, University of Arizona, Tucson,
Arizona (S.G., C.C.S., K.J.M., R.B.B.); Developmental Therapeutics
Program, Division of Cancer Treatment and Diagnosis, National Cancer
Institute, National Institutes of Health, Rockville, Maryland (E.A.S.);
and Department of Chemistry and Biochemistry and Cancer Research
Institute, Arizona State University, Tempe, Arizona (G.R.P.)
The successful synthesis of dolastatin 11, a depsipeptide originally
isolated from the mollusk Dolabella auricularia,
permitted us to study its effects on cells. The compound arrested cells at cytokinesis by causing a rapid and massive rearrangement of the
cellular actin filament network. In a dose-and time-dependent manner,
F-actin was rearranged into aggregates, and subsequently the cells
displayed dramatic cytoplasmic retraction. The effects of dolastatin 11 were most similar to those of the sponge-derived depsipeptide
jasplakinolide, but dolastatin 11 was about 3-fold more cytotoxic than
jasplakinolide in the cells studied. Like jasplakinolide, dolastatin 11 induced the hyperassembly of purified actin into filaments of
apparently normal morphology. Dolastatin 11 was qualitatively more
active than jasplakinolide and, in a quantitative assay we developed,
dolastatin 11 was twice as active as jasplakinolide and 4-fold more
active than phalloidin. However, in contrast to jasplakinolide and
phalloidin, dolastatin 11 did not inhibit the binding of a fluorescent
phalloidin derivative to actin polymer nor was it able to displace the
phalloidin derivative from polymer. Thus, despite its structural
similarity to other agents that induce actin assembly (all are peptides
or depsipeptides), dolastatin 11 may interact with actin polymers at a
distinct drug binding site.
This article has been cited by other articles:
![]() |
C. L. Cordero, D. S. Kudryashov, E. Reisler, and K. J. F. Satchell The Actin Cross-linking Domain of the Vibrio cholerae RTX Toxin Directly Catalyzes the Covalent Cross-linking of Actin J. Biol. Chem., October 27, 2006; 281(43): 32366 - 32374. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. S. Kudryashov, M. Phillips, and E. Reisler Formation and Destabilization of Actin Filaments with Tetramethylrhodamine-Modified Actin Biophys. J., August 1, 2004; 87(2): 1136 - 1145. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Cruz-Monserrate, H. C. Vervoort, R. Bai, D. J. Newman, S. B. Howell, G. Los, J. T. Mullaney, M. D. Williams, G. R. Pettit, W. Fenical, et al. Diazonamide A and a Synthetic Structural Analog: Disruptive Effects on Mitosis and Cellular Microtubules and Analysis of Their Interactions with Tubulin Mol. Pharmacol., June 1, 2003; 63(6): 1273 - 1280. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Bai, D. G. Covell, C. Liu, A. K. Ghosh, and E. Hamel (-)-Doliculide, a New Macrocyclic Depsipeptide Enhancer of Actin Assembly J. Biol. Chem., August 23, 2002; 277(35): 32165 - 32171. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. A. Ojo-Amaize, E. J. Nchekwube, H. B. Cottam, R. Bai, P. Verdier-Pinard, V. N. Kakkanaiah, J. A. Varner, L. Leoni, J. I. Okogun, A. A. Adesomoju, et al. Hypoestoxide, a Natural Nonmutagenic Diterpenoid with Antiangiogenic and Antitumor Activity: Possible Mechanisms of Action Cancer Res., July 15, 2002; 62(14): 4007 - 4014. [Abstract] [Full Text] [PDF] |
||||